VANCOUVER, British Columbia, July 10, 2019 (GLOBE NEWSWIRE) — Emerald Well being Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 9,960 40-ml models of its SYNC 25 CBD oil to Alberta and Saskatchewan. The Emerald-branded Indica-dominant CBD oil presents customers a smoke-free product various.

CBD oil has grow to be an more and more common product available on the market as we speak, and our cannabis-derived SYNC 25 is an instance of the high-quality merchandise that customers can anticipate from Emerald,” stated Dr. Avtar Dhillon, President and Govt Chairman of Emerald. “With our vary of experience within the analysis and improvement of science-driven merchandise, we’ll proceed to develop our product portfolio and meet shopper demand.”

SYNC 25 has been shipped to Alberta Gaming, Liquor and Hashish and to personal retailers approved by the Saskatchewan Liquor and Gaming Authority. In Could, Emerald shipped 6,000 40-ml models of SYNC 25 to the British Columbia Liquor Distribution Department.

About Emerald Well being Therapeutics, Inc.

Emerald Well being Therapeutics, Inc. is a Canadian licensed producer of cannabis merchandise, with strategic initiatives centered on differentiated, value-added product improvement for medical and adult-use prospects supported by novel mental property, large-scale cultivation, extraction, and softgel encapsulation, in addition to distinctive advertising and marketing and distribution channels. Its 50%-owned Pure Sunfarms operation in British Columbia is in full manufacturing in its first 1.1 million sq. foot greenhouse, with rising capability of roughly 75,000 kg; a second 1.1 million sq. foot greenhouse is deliberate to be in full manufacturing by the top of 2020. Emerald’s two different wholly-owned amenities in Québec, a high-quality indoor rising and processing facility, and British Columbia, an natural greenhouse and outside operation, are finishing building and are working towards remaining allowing. Emerald has additionally contracted for about 1,200 acres of hemp yearly in 2019 to 2022 with the target of extracting low-cost CBD. Its crew is extremely skilled in life sciences, product improvement, large-scale agri-business, and advertising and marketing.

Emerald is a part of the Emerald Well being group, which represents a broad array of firms centered on growing pharmaceutical, botanical, and nutraceutical merchandise aimed toward offering wellness and medical advantages by interacting with the human physique’s endocannabinoid system.

For additional details about Emerald Well being Therapeutics.

Please go to www.emeraldhealth.ca or contact:

Rob Hill, Chief Monetary Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
[email protected]

Neither the TSX Enterprise Trade nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Trade) accepts accountability for the adequacy or accuracy of this launch.

Cautionary Notice Concerning Ahead-Wanting Statements: Sure statements made on this press launch that aren’t historic information are forward-looking statements and are topic to essential dangers, uncertainties and assumptions, each normal and particular, which give rise to the likelihood that precise outcomes or occasions may differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements embrace manufacturing and processing capability of assorted amenities; growth of amenities; anticipated manufacturing prices; acquisition of hemp; improvement and sale of merchandise; and growth of product portfolio.

We can’t assure that any forward-looking assertion will materialize, and readers are cautioned to not place undue reliance on these forward-looking statements. These forward-looking statements contain dangers and uncertainties associated to, amongst different issues, failure to acquire regulatory approvals; failure to acquire essential financing; outcomes of manufacturing and sale actions; outcomes of scientific analysis; regulatory adjustments; adjustments in costs and prices of inputs; demand for labour; demand for merchandise; in addition to the danger elements described within the Firm’s annual info type and different regulatory filings. The forward-looking statements contained on this press launch symbolize our expectations as of the date hereof. Ahead-looking statements are introduced for the aim of offering details about administration’s present expectations and plans and permitting traders and others to acquire a greater understanding of our anticipated working atmosphere. Readers are cautioned that such info will not be applicable for different functions. The Firm undertakes no obligations to replace or revise such statements to replicate new circumstances or unanticipated occasions as they happen, until required by relevant regulation.

Primary Logo